华润医疗(01515.HK):签订重组协议 正式落实于京煤集团下属医疗机构开展合资共建的股权架构及合作模式
格隆汇 6 月 28日丨华润医疗(01515.HK)公布,2020年6月28日,公司下属全资子公司华润医院控股与京煤集团签订了重组协议,正式落实订约方于京煤集团下属医疗机构开展合资共建的股权架构及合作模式,相关的安排如下:
(1)合资举办权公司:由华润医院控股与京煤集团成立合资举办权公司,其成立后将由京煤集团注入彼持有的目标医院集团全部产权以作增资,同时华润医院控股则以现金增资。当中华润医院控股及京煤集团将分别持有合资举办权公司49%及51%的股权。
(2)合资管理公司:由华润医院控股与京煤集团成立合资管理公司。合资管理公司的注册资本将随后由华润医院控股及京煤集团分别以现金出资。当中华润医院控股及京煤集团将分别持有合资管理公司49%及51%的股权。
(3)目标医院集团管理安排:京煤集团、合资管理公司及目标医院将比照原京煤IOT协议有关内容签订京煤OT协议,并按此由合资管理公司向目标医院集团提供医院管理服务并收取管理费收益。
集团自2011年起与目标医院集团以IOT(即“投资—运营—移交”)模式开展了合作共建改革。期内集团为目标医院注入发展资金和资源,并通过多项措施提升目标医院的各项水平,包括:1.实施对目标医院集团的院区改造和流程优化以改善诊疗环境;2.通过引进设备等方式提升目标医院集团的技术水准和服务水准;及3.通过优化薪酬体系建立员工收入持续增长机制。改革后目标医院已成为京西地区一所三级精品综合医院。自合作以来的9年间,目标医院集团的年收入已从人民币4.4亿元快速增长至人民币14.5亿元,年门诊量则从46.7万增长至156.3万人次,年出院人次从1.23万人次增长至3.46万人次。特别是三、四级手术量、介入操作量、内镜量等体现医疗技术水准的重要指标,均实现了15%以上的年均复合增长,充分展现了集团较强的医院运营管理能力及其为医院发展赋能的能力,保障了国有资产的持续增值。
此次重组协议的签订旨在充分发挥京煤集团及集团各自的优势并共同对目标医院集团实行改革和重组,为目标医院集团进一步引入发展资金、医疗资源和管理资源,并强化其管理体制和运行机制。重组协议项下的合作模式在原有IOT模式的基础之上更进一步,在资产层面深化推进改革合作,一是通过转变合作机制,将委托管理关系深化为股权合作关系,巩固了合作基础,进一步稳固了集团与目标医院集团的管理关系;二是此次改革为目标医院集团继续引入发展资金,进一步深化体制机制改革,提高其核心竞争力,保障其可持续发展;三是通过此次合作拓展京煤医院周边业务用途;四是从IOT模式向产权合作模式过渡,为全国国有企业深化辅业资产改革提供了可资借鉴的分阶段式改革案例。目标医院集团目前年收入达14.5亿元,已成为门头沟区的龙头医院,也是京西地区的核心医疗机构之一,资源价值稀缺。通过此次改革,有助于集团在北京市内获取稀缺战略资源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.